My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
RTP Chpt: Jointly venturing to find a cure for HIV/AIDS
Tell a Friend About This EventTell a Friend
RTP Chpt: Jointly venturing to find a cure for HIV/AIDS

“Why Companies and Universities Should Forge Long-Term Collaborations” Join us for an exciting panel discussion by GlaxoSmithKline and University of North Carolina on the formation and implementation of their joint venture for this unmet need.

When: Thursday, September 5, 2019
5:30 pm - 8:30 pm EDT
Where: Mez Contemporary Mexican
5410 Page Rd.
Durham, North Carolina  27703
United States
Contact: Parth Amin

Online registration is closed.
« Go to Upcoming Event List  

To register for this face-to-face local community event, click on Register above.

“Why Companies and Universities Should Forge Long-Term Collaborations”

In the January 24, 2018 Harvard Business Review article “Why Companies and Universities Should Forge Long-Term Collaborations”, the author Kenneth R. Lutchen – Dean of Boston University’s College of Engineering – states:


“Both industry and academia stand to benefit from long-term cooperation. Companies will gain greater access to cutting-edge research and scientific talent at a time when corporate R&D budgets are increasingly under pressure. Universities will gain access to financial support and partners in research at a time when government funding is shrinking. Most importantly, society will benefit from a stream of previously unimaginable advances — in life sciences, biomedical engineering, communications, environmental sciences, artificial intelligence, and more — that will vastly improve everyone’s life.”


However, this was already understood by the University of North Carolina at Chapel Hill (UNC) and GlaxoSmithKline (GSK) back in 2015 when they began discussions to explore a collaborative relationship with the lofty ambition to discover a cure for HIV/AIDS. They realized this partnership through the formation of the UNC HIV Cure Center and co-founded a jointly owned company, Qura Therapeutics, which handles the business side of the partnership.This incredibly unique public-private partnership is redefining the traditional way of conducting research and is creating a new model to seek the breakthroughs needed to tackle an extraordinarily challenging global health issue.In October of 2018, the ViiV Healthcare Discovery Unit and GSK’s HIV Discovery Performance Unit (DPU) merged and ViiV assumed GSK roles and responsibilities as it pertains to the partnership.


Come join us for this exciting panel discussion as we learn from both GSK and UNC on the formation and implementation of this public / private joint venture and in particular:



  • Why a Joint Venture vs. other partnership models 
  • Managing expectations during a multi-year negotiation effort 
  • Overcoming key sticking points in the negotiation of a JV 
  • Decision maker alignment on such an ambitious strategic intent 
  • Managing the logistical details of a deal like this: co-location, employment, operational resources, etc.


  • Overcoming cultural differences 
  • Ensuring stakeholder alignment and support
  • Appropriate Level of Governance


  • How this could be blueprint for future university and industry collaborations 
  • Would they do it again 
  • What could have been done differently


Mary Napier | Director of Operations, UNC HIV Cure Center | University of North Carolina at Chapel Hill

Jackie Quay Director, Licensing & Innovation Support, Office of Technology Commercialization | University of North Carolina at Chapel Hill

Brian A. Johns, Ph.D. | VP of External Discovery Sciences | ViiV Healthcare



Parth Amin, CSAP | Founding Principal | Alliance Dynamics, LLC


Click Here for Agenda

The ASAP RTP chapter would like to thank GlaxoSmithKline for hosting this event.

For more information email us at or call +1-781-562-1630